BioVie Inc (NASDAQ:BIVI, NASDAQ:BIVIW) announced that an abstract from its SUNRISE-PD study evaluating its lead candidate bezisterim (NE3107) for Parkinson’s disease has been accepted for presentation ...

“The findings from the SYMON-I study suggest that IL-6 measured in the emergency department may be associated with subsequent organ dysfunction in patients with sepsis and septic shock. These data ...

BioVie Inc. (NASDAQ: BIVI) ('BioVie” or the 'Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of ...

Maharashtra National Law University, Nagpur (MNLU Nagpur) is organising a Two-Day National Conference titled “Four Decades of the NDPS Act, 1985: Jurisprudential Evolution, Contemporary ...

The MarketWatch News Department was not involved in the creation of this content. BURLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- COMSOL, an independently-owned global leader in modeling and ...

National Conference is Road Safety GB’s flagship event, with the 2026 edition – the 16 th – being held at The Queens Hotel, Leeds on 24-25 November 2026. For the past three years around 400 road ...

PITTSBURGH, PA, UNITED STATES, March 6, 2026 /EINPresswire.com/ -- For more than 25 years, Cribs for Kids has worked ...

The CitiesAlive 2026 in Brooklyn this September Call for Proposals & Research Papers is Open & the Deadline to Submit is ...

Building on the recent U.S. FDA Fast Track Designation for AJ201 (Rosolutamide) and encouraging Phase 2 clinical results, AnnJi presented two scientific abstracts spanning translational transcriptomic ...

CRT is one of the world’s leading educational forums for interventional cardiovascular medicine, with Top Abstract podium selections representing the highest-scoring submissions based on scientific ...

Produced by SAF Magazine and organized by BBI International in Collaboration with CAAFI TACOMA, WA, UNITED STATES, ...

Week-48 suppression was 91.8% with DOR/ISL vs 90.6% with BIC/FTC/TAF, with few discontinuations for inefficacy and similar overall tolerability. EMBRACE reported 12-month suppression rates of 94% (IV ...